Clin Transplant Res
Published online November 8, 2024
© The Korean Society for Transplantation
Dong Han Kim1 , Tae Hyun Ryu2 , Hee Yeoun Kim2 , Jeong Myung Ahn2 , Joon Seok Oh2 , Joong Kyung Kim2
1Division of Nephrology, Department of Internal Medicine, Gupo Sungshim Hospital, Busan, Korea
2Division of Nephrology, Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea
Correspondence to: Joon Seok Oh
Division of Nephrology, Department of Internal Medicine, Bong Seng Memorial Hospital, 401 Jungang-daero, Dong-gu, Busan 48775, Korea
E-mail: j-seok@hanmail.net
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Vaccine-induced hypermetabolic lymph nodes have been clinically observed following coronavirus disease 2019 (COVID-19) mRNA vaccination. Specifically, the booster dose of the mRNA vaccines, produced by Pfizer and Moderna, has been linked to a relatively high incidence of lymphadenopathy. We present the case of a kidney transplant recipient who developed an enlarged abdominal mass after receiving a booster dose of the COVID-19 mRNA vaccine. This mass occupied the retroperitoneal space, infiltrated the psoas muscle, and resulted in ureteric compression and hydronephrosis. Percutaneous drainage and analysis of the perirenal fluid revealed the presence of lymphatic fluid. In summary, lymphadenopathy is a recognized adverse reaction to the Pfizer and Moderna vaccines. Patients with compromised immune systems should be informed about the incidence and potential severity of lymphadenopathy following booster vaccination.
Keywords: COVID-19, Vaccine, Kidney, Transplant recipient, Lymphadenopathy